Rapid Response, Low-Cost Vaccine Manufacturing

Welcome to the replay of our webinar hosted by Batavia Biosciences in partnership with DCVMN. This informative session, titled “Rapid Response, Low-Cost Manufacturing of Viral Vaccines Against Emerging Infectious Disease Threats,” addressed some of the most pressing issues in today’s global health landscape.

Dealing with Emerging Threats Infectious Disease

In a world where vaccine inequality and public hesitancy continue to plague our efforts to increase coverage, it is essential to adapt and innovate. Did you know that approximately 25 million children under the age of one did not receive essential vaccines, marking the highest count since 2009? During the COVID-19 pandemic, global vaccine coverage fell to 81%, with a mere 29% of the population in developing countries receiving vaccinations against Covid.

The challenges we face may seem overwhelming, but through the advancements in our HIP-Vax platform, we believe we’re poised to make a significant difference. The HIP-Vax platform aims to shorten the time it takes to bring vaccines to the clinic, dramatically reducing manufacturing costs.

Our speaker for the session was Alfred Luitjens, the Global Technical Sales Director at Batavia Biosciences. Alfred is well-versed in the complexities of vaccine production and eager to share insights into how we can work towards a more equitable future through innovative solutions.


The Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary alliance of over 40 vaccine manufacturers from 15 developing countries, firmly engaged in innovation, research, development, manufacturing, and supply of high-quality vaccines to 170 countries striving to enable equitable access to vaccines.

DCVMN aims to protect people against known and emerging infectious diseases globally by increasing the production of high-quality vaccines in developing countries. It works to strengthen vaccine manufacturers through the provision of advocacy, professional training programs on technological and production improvements, and acting as a liaison to foster partnerships and funding. DCVMN also encourages technology transfer initiatives and educates the public about the availability of safe, effective and affordable vaccines for all people.

Read more on their website.


Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression